Table 2 Observed versus predicted patient response rates to glofitamab monotherapy treatment

From: QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy

 

Glofitamab (predictions)

Response

Sims

Obs

CR

33.83

33

PR

13.28

15

SD

38.97

 

PD

13.92

 
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease.
  2. The response classification is based on ref. 48.
  3. Glofitamab clinical data from n = 127 aggressive-NHL patients28.
Back to article page